Cargando…

LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes

BACKGROUND: Leptomeningeal disease (LMD) occurs in 3–5% of patients with solid metastatic tumors and often portends a severe prognosis including symptomatic hydrocephalus and intracranial hypertension. Cerebrospinal fluid (CSF) shunting can provide symptomatic relief in this patient subset; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bander, Evan D, Yuan, Melissa, Reiner, Anne S, Garton, Andrew, Panageas, Katherine S, Brennan, Cameron W, Tabar, Viviane, Moss, Nelson S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351259/
http://dx.doi.org/10.1093/noajnl/vdab071.027
_version_ 1783735936063897600
author Bander, Evan D
Yuan, Melissa
Reiner, Anne S
Garton, Andrew
Panageas, Katherine S
Brennan, Cameron W
Tabar, Viviane
Moss, Nelson S
author_facet Bander, Evan D
Yuan, Melissa
Reiner, Anne S
Garton, Andrew
Panageas, Katherine S
Brennan, Cameron W
Tabar, Viviane
Moss, Nelson S
author_sort Bander, Evan D
collection PubMed
description BACKGROUND: Leptomeningeal disease (LMD) occurs in 3–5% of patients with solid metastatic tumors and often portends a severe prognosis including symptomatic hydrocephalus and intracranial hypertension. Cerebrospinal fluid (CSF) shunting can provide symptomatic relief in this patient subset; however, few studies have examined the role of shunting in the palliation, prognosis and overall oncologic care of these patients. OBJECTIVE: To identify and evaluate risk factors associated with prognosis after CSF diversion and assess surgical, symptomatic and oncologic outcomes in this population. METHODS: A retrospective study was conducted on patients with solid-malignancy LMD treated with a shunt at an NCI-designated Comprehensive Cancer Center between 2010–2019. RESULTS: One hundred and ninety patients with metastatic LMD underwent CSF diversion. Overall survival was 4.14 months from LMD diagnosis (95%CI:3.29–4.70) and 2.43 months (95%CI:2.01–3.09) from shunting. KPS at time of shunting and BrM number at LMD diagnosis demonstrated significant associations with survival (HR=0.66; 95%CI[0.51–0.86], p=0.002; HR=1.40; 95%CI[1.01–1.93] per 10 BrM, p=0.04, respectively). Eighty-three percent of patients experienced symptomatic relief, and 79% were discharged home or to rehabilitation facilities post-shunting. Post-shunt, 56% of patients received additional systemic therapy or started or completed WBRT. Complications included infection (5%), symptomatic subdural hygroma/hematoma (6.3%), and shunt externalization/removal/repair (8%). Abdominal seeding was not identified. CONCLUSIONS: CSF diversion for LMD with hydrocephalus and intracranial hypertension secondary to metastasis can achieve symptomatic relief, hospital discharge, and return to further oncologic therapy, with a complication profile unique to this pathophysiology. However, decision-making in this population must incorporate end-of-life goals of care given limited prognosis.
format Online
Article
Text
id pubmed-8351259
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83512592021-08-09 LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes Bander, Evan D Yuan, Melissa Reiner, Anne S Garton, Andrew Panageas, Katherine S Brennan, Cameron W Tabar, Viviane Moss, Nelson S Neurooncol Adv Supplement Abstracts BACKGROUND: Leptomeningeal disease (LMD) occurs in 3–5% of patients with solid metastatic tumors and often portends a severe prognosis including symptomatic hydrocephalus and intracranial hypertension. Cerebrospinal fluid (CSF) shunting can provide symptomatic relief in this patient subset; however, few studies have examined the role of shunting in the palliation, prognosis and overall oncologic care of these patients. OBJECTIVE: To identify and evaluate risk factors associated with prognosis after CSF diversion and assess surgical, symptomatic and oncologic outcomes in this population. METHODS: A retrospective study was conducted on patients with solid-malignancy LMD treated with a shunt at an NCI-designated Comprehensive Cancer Center between 2010–2019. RESULTS: One hundred and ninety patients with metastatic LMD underwent CSF diversion. Overall survival was 4.14 months from LMD diagnosis (95%CI:3.29–4.70) and 2.43 months (95%CI:2.01–3.09) from shunting. KPS at time of shunting and BrM number at LMD diagnosis demonstrated significant associations with survival (HR=0.66; 95%CI[0.51–0.86], p=0.002; HR=1.40; 95%CI[1.01–1.93] per 10 BrM, p=0.04, respectively). Eighty-three percent of patients experienced symptomatic relief, and 79% were discharged home or to rehabilitation facilities post-shunting. Post-shunt, 56% of patients received additional systemic therapy or started or completed WBRT. Complications included infection (5%), symptomatic subdural hygroma/hematoma (6.3%), and shunt externalization/removal/repair (8%). Abdominal seeding was not identified. CONCLUSIONS: CSF diversion for LMD with hydrocephalus and intracranial hypertension secondary to metastasis can achieve symptomatic relief, hospital discharge, and return to further oncologic therapy, with a complication profile unique to this pathophysiology. However, decision-making in this population must incorporate end-of-life goals of care given limited prognosis. Oxford University Press 2021-08-09 /pmc/articles/PMC8351259/ http://dx.doi.org/10.1093/noajnl/vdab071.027 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Abstracts
Bander, Evan D
Yuan, Melissa
Reiner, Anne S
Garton, Andrew
Panageas, Katherine S
Brennan, Cameron W
Tabar, Viviane
Moss, Nelson S
LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
title LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
title_full LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
title_fullStr LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
title_full_unstemmed LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
title_short LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
title_sort lmd-02. cerebrospinal fluid diversion for metastatic leptomeningeal carcinomatosis: palliative, procedural and oncologic outcomes
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351259/
http://dx.doi.org/10.1093/noajnl/vdab071.027
work_keys_str_mv AT banderevand lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes
AT yuanmelissa lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes
AT reinerannes lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes
AT gartonandrew lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes
AT panageaskatherines lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes
AT brennancameronw lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes
AT tabarviviane lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes
AT mossnelsons lmd02cerebrospinalfluiddiversionformetastaticleptomeningealcarcinomatosispalliativeproceduralandoncologicoutcomes